Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symbicort Single Inhaler Therapy vs Conventional Best Practice in Persistent Asthma
NCT00252824Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2005
- Modality
- Orthosteric Ligands
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of budesonide in asthma (2 arms), sponsored by AstraZeneca. Primary endpoint: Time to first severe asthma exacerbation at 26 weeks. Started Jul 2005; status: completed.
02
Drugs
budesonide
03
Conditions
asthma
Beyond the preview
Go deeper on NCT00252824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00252824.